Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,237 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Infected Clear all
Completed Phase 3 Interventional Results available

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

NCT00272779
View directory record Official record
Conditions
HIV Infections
Interventions
ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet, LPV
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Phoenix, Arizona • Laguna Beach, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Not applicable Interventional

A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients

NCT00002223
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Maitland, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Jun 26, 2026, 2:43 PM EDT
Terminated Not applicable Interventional Results available

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

NCT01293123
View directory record Official record
Conditions
HIV
Interventions
Raltegravir, Efavirenz
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Not applicable Interventional

Study of Home-Based Resistance and Strength Training in HIV-Infected Women

NCT00111332
View directory record Official record
Conditions
HIV Infections
Interventions
Progressive resistance and aerobic training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Jun 26, 2026, 2:43 PM EDT
Withdrawn No phase listed Observational

A Study of Patients Who Recently Have Been Infected With HIV

NCT00006415
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Horsham, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jun 26, 2026, 2:43 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

NCT01866930
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Pegylated Interferon Lambda-1a, Daclatasvir (DCV), Ribasphere (RBV)
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
13
States / cities
Rialto, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

NCT00000792
View directory record Official record
Conditions
HIV Infections
Interventions
Hypericin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00080106
View directory record Official record
Conditions
HIV Infections
Interventions
MRK Ad5 HIV-1 gag vaccine, Vaccine placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jun 26, 2026, 2:43 PM EDT
Withdrawn Phase 3 Interventional

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

NCT01605084
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

NCT00002233
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

NCT00000822
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine, Didanosine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

NCT00002436
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine, Zalcitabine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pre-HIV Test Counseling Intervention to Reduce HIV Infection Risk Behavior in Men Who Are Not HIV Infected

NCT00218699
View directory record Official record
Conditions
HIV Infections
Interventions
Cognitive-Behavioral Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

NCT00002363
View directory record Official record
Conditions
HIV Infections
Interventions
Peptide Construction 3, Synthetic
Drug
Lead sponsor
Columbia Research Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People

NCT02191098
View directory record Official record
Conditions
HIV, Stable ART
Interventions
ALT-803
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Not applicable Interventional

A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients

NCT00002000
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
Mobile, Alabama • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

Functional Interval Training for Veterans Exercising Through Telehealth.

NCT04103593
View directory record Official record
Conditions
HIV Infection
Interventions
exercise training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 26, 2026, 2:43 PM EDT
Terminated Phase 1 Interventional

Lymphocyte Infusions for the Treatment of HIV-Infected Patients Failing Anti-HIV Therapy

NCT00559416
View directory record Official record
Conditions
HIV Infections
Interventions
Cell Transfer
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jun 26, 2026, 2:43 PM EDT
Withdrawn No phase listed Observational

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

NCT01394133
View directory record Official record
Conditions
HIV Infected
Interventions
Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

NCT00000984
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

NCT00002332
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Tarzana, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Not applicable Interventional

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

NCT00000914
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jun 26, 2026, 2:43 PM EDT
Completed Not applicable Interventional

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

NCT00000744
View directory record Official record
Conditions
Candidiasis, Candidiasis, Esophageal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 26, 2026, 2:43 PM EDT